PubMed Health⌕ Search

Biomedical subjects

M C Copeman

Publications and source records attributed to M C Copeman.

10 recordsLinked to original sources
PubMed1993

Pneumomediastinum complicating childhood acute lymphoblastic leukaemia.

A case of pneumomediastinum that developed in a 10 year old girl receiving induction chemotherapy for acute lymphoblastic leukemia is reported. Three factors were identified that may have been associated with this complication: the patient suffered recurrent vomiting during her induction chemotherapy; she had travelled by air the day before the pneumo mediastinum was diagnosed; and was septic with Enterobacter at time of diagnosis. The pneumomediastinum resolved over 2 weeks without specific treatment and without further complications.

Air Pressure↗
PubMed1992

The putative melanoma tumor-suppressor gene on human chromosome 6q.

The tumorigenicity of malignant melanoma cells may be suppressed experimentally by the introduction into these cells of human chromosome 6 or mouse chromosome 4. These chromosomes share a homologous region, contained in human chromosome 6q12-21. Abnormalities of this human chromosomal region have been found frequently not only in cutaneous and uveal malignant melanomas, but also in a range of other tumors. In all these, mutations of tumor-suppressor genes on human chromosome 6q may be involved. Identification of this putative tumor-suppressor gene may give new insights into the biology of malignant melanomas, and could pave the way for new treatment for such tumors, based upon the tumor-suppressor protein which this gene is likely to encode.

Animals↗
PubMed1988

Presenting symptoms of neoplastic spinal cord compression.

The cases of 28 patients with neoplastic spinal cord compression were reviewed. The most common presenting symptoms were: back pain (68%), bilateral leg weakness (61%), urinary retention (36%), and bilateral leg numbness (32%). Twelve patients (43%) had known neoplastic disease prior to diagnosis of spinal cord compression. Only two patients (7%) were diagnosed within one week of the onset of major spinal symptoms. The commonest symptoms associated with delay in diagnosis were again back pain (50%) and bilateral leg weakness (38%). However, when certain symptoms were present, diagnosis was almost always delayed, particularly with unilateral leg weakness or pain (100%), ataxic gait (80%), and back pain (68%). Symptoms in the neck, chest, and arms were also always associated with delayed diagnosis.

Adult↗
PubMed1988

The extracellular matrix of hybrids between melanoma cells and normal fibroblasts.

It has been shown that when malignant tumour cells are fused with normal fibroblasts the suppression of malignancy in the hybrids is linked to their ability to produce a collagenous extracellular matrix in vivo. When, as a consequence of chromosome loss, segregants arise that reacquire malignancy, these do not produce any detectable matrix. In this paper we examine the main components of the extracellular matrix produced in vitro by hybrids between malignant mouse melanoma cells and normal mouse fibroblasts. Hybrids in which malignancy is suppressed synthesize about ten times as much type 1 procollagen as the malignant segregants derived from them; they also retain more fibronectin in the cell layer and release less protease activity into the medium. Malignant segregants more closely resemble the parental melanoma cells in producing fibronectin and mainly types IV and V procollagen. When hybrid cells in which malignancy is initially suppressed are grown continuously in vitro, the production of type I procollagen declines, and the production of type V procollagen and the release of protease activity into the medium increase. These changes, which are associated with the loss from the hybrid cells of both copies of the chromosome 4 derived from the parental fibroblast, predict the reacquisition of malignancy when the cells are inoculated into mice. It is possible that one gene or set of genes located on chromosome 4 determines both the execution of the fibroblast differentiation programme and the suppression of malignancy.

Animals↗
PubMed1987

Desensitization to DNFB in hairless mice.

Naive hairless mice may be rendered partly tolerant to dinitrofluorobenzene (DNFB) by painting DNFB on skin irradiated with 30 mJ.cm-2 ultraviolet B light (UVB) over 4 days. However, DNFB-sensitized hairless mice show no decrease in sensitivity when repainted with DNFB on skin irradiated with the same dose of UVB. Hence, established hypersensitivity appears not to be reduced by this method of inducing tolerance in naive mice.

Animals↗
PubMed1985

Arterial Brown-Séquard's syndrome after a penetrating injury of the spinal cord at the cervicomedullary junction.

A case of a 12-year-old boy, in whom a partial Brown-Séquard's syndrome developed after a gunshot injury to the back of the neck, is reported. The bullet, which was removed at operation, penetrated the left side of the spinal cord at the cervicomedullary junction. The patient recovered useful function in his left leg within a month after the injury, and was able to walk with the aid of a crutch on discharge from hospital. The case is unusual, because of the survival and subsequent good recovery of the patient after a high, penetrating injury of the spinal cord.

Child↗
PubMedDate not supplied

Use of total parenteral nutrition in children with cancer: a review and some recommendations.

Total parenteral nutrition (TPN) is now a standard component of supportive treatment in many pediatric oncology units for patients undergoing intensive therapy. TPN incurs many risks and significant costs, however, that may not always be balanced by major benefits. Infection rates are reported to be high in patients receiving TPN, and TPN use is associated with a range of metabolic problems. With standard TPN regimens, the catabolic state of many intensively treated patients may not be adequately reversed. Because TPN may enhance tumor cell growth, there is justifiable concern about giving TPN when a cancer patient is not also receiving cytotoxic therapy. Recommendations for TPN use in pediatric oncology patients include using TPN formulas containing glutamine to stimulate anabolism and timing TPN cycles to be given just before cytotoxic chemotherapy, when stimulation of tumor growth might actually improve the effectiveness of antimitotic chemotherapy.

Animals↗